Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046462 · ClinicalTrials.gov registry record · Phase 3
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00046462 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 240 participants.
The verdict
NCT00046462, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
Interventions
- DRUG Metformin
- DRUG Lantus (insulin glargine [rDNA origin] injection)
- DRUG Thiazolidinedione
- DRUG Glyburide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2001-11 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046462
The ClinicalTrials.gov registry entry for NCT00046462 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT00046462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046462 about?
NCT00046462 is a clinical study titled "Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment". The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
What is the current status of trial NCT00046462?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2001-11. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00046462?
The interventions under investigation include: Metformin (DRUG), Lantus (insulin glargine [rDNA origin] injection) (DRUG), Thiazolidinedione (DRUG), Glyburide (DRUG).
Who is sponsoring clinical trial NCT00046462?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.